

International Antiviral Society–USA

MISSION

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

ACCREDITATION STATEMENT

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SCIENTIFIC LEADERSHIP BOARD

The Scientific Leadership Board of volunteers guides the needs assessment, design, development, and evaluation of the educational and scientific programming of the in-person and virtual courses, webinars and *Topics in Antiviral Medicine*[™]. Visit <https://www.iasusa.org/about/ias-usa-scientific-leadership-bod/> for a list of Scientific Leadership Board members.

IAS–USA GOVERNANCE

The IAS–USA Governance members provide administrative oversight for the operations and mission of the IAS–USA. Non-Staff Members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. Visit <https://www.iasusa.org/about/ias-usa-governance/> for a list of IAS–USA Governance members.

IMPROVING THE MANAGEMENT OF HIV DISEASE®: ADVANCED CME COURSES IN HIV PATHOGENESIS, ANTIRETROVIRALS, AND OTHER SELECTED ISSUES IN HIV DISEASE MANAGEMENT

These one-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. The virtual courses are half-day update that focus on the key issues clinicians are likely facing. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. Visit www.iasusa.org/activities/live-courses/hiv-courses/ for more information on upcoming and on-demand CME courses.

WEBINARS

The IAS–USA offers state-of-the-art webinars on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. They are led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and provides continuing education credits. Visit www.iasusa.org/activities/webinars/upcoming-webinars/ for upcoming webinars. On-demand webinars offer CME credit for

a year at www.iasusa.org/activities/webinars/on-demand-webinars/.

Webinar topics and presenters are identified by the *Cases on the Web Board (COW)* Board, a select group of experts in the management of HIV and other viral infections. Visit www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ for a list of COW Board members.

CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS

The IAS–USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014 to 2023 are available at www.CROIconference.org.

CROI 2024 will be held in Denver, Colorado, from March 3 to 6, 2024.

RYAN WHITE HIV/AIDS PROGRAM CLINICAL CONFERENCE

The Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS–USA). This conference is coordinated through the AIDS Education and Training Centers (AETC) clinician training network.

RWHAP CLINICAL CONFERENCE will be held in Portland, Oregon, from December 3 to 5, 2023.

TOPICS IN ANTIVIRAL MEDICINE[™]

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine*[™] 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of people with HIV or other viral infections. The journal offers CME credit and is indexed on Index Medicus/MEDLINE. Visit <https://www.iasusa.org/activities/topics-in-antiviral-medicine/current-issues/> to view the journal.

TREATMENT AND TESTING GUIDELINES

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA volunteer Antiretroviral Guidelines Panel, were last

published in the *Journal of the American Medical Association* on December 1, 2022 (Gandhi RT, Bedimo RJ, Hoy JF et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel. *JAMA*. 2022:E1-22). *JAMA* offers free access to the paper at <https://jamanetwork.com/journals/jama/fullarticle/2799240>. The 2022 iteration includes updated recommendations on initiating and changing antiretroviral therapy, prevention of HIV infection, and comorbidities in the setting of antiretroviral therapy. New sections include substance use disorder recommendations and new and emerging coinfections such as MPOX.

HIV DRUG RESISTANCE MUTATIONS

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. A volunteer panel of acknowledged leaders in the field collect and review the information on relevant mutations. This information, last updated in October 2022, is available on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

COVID-19: WHAT WE KNOW TODAY. A DIALOGUE ABOUT THE PUBLIC HEALTH, SCIENTIFIC, AND CLINICAL ASPECTS OF THE PANDEMIC

The COVID-19 pandemic has created an urgent need for reliable scientific information. The IAS–USA COVID-19 Dialogues bring together 2 or more leading experts to discuss the latest science regarding COVID-19 and what the data and research are telling us about the basic science, public health,

and clinical aspects of the disease, and the consequences of the pandemic.

Visit <https://www.iasusa.org/activities/covid-19-dialogue-series/> for upcoming live Dialogues. The conversations are available on-demand as webcasts and podcasts after they are broadcast at www.iasusa.org/activities/covid-19-dialogue-series/on-demand/.

PODCASTS

Many past IAS–USA activities are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations.

PRACTICE QUESTION OF THE WEEK

This initiative started in 2021 and highlights updates to relevant practice guidelines or identified practice gaps. Each question is programmed as a pop-up and on the [resources page](#) on the IAS–USA website. Participants receive immediate feedback with the correct answer, explanation, and links to more resources. Visit <https://www.iasusa.org/practice-question-of-the-week/> to view the most recent question and to see past questions.

PRESENTATION SLIDES

The IAS–USA offers a collection of downloadable slides from presentations at conferences or past IAS–USA live courses. Presenters have selected the slides they consider the most informative and relevant. Slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.



For information about any of these programs, please visit www.IAS-USA.org.

Email: info@iasusa.org • Phone: (415) 544-9400